{"Symbol": "CFRX", "AssetType": "Common Stock", "Name": "ContraFect Corporation", "Description": "ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin, which has completed Phase II clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic influenza infections. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting gram-negative pathogens; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Healthcare", "Industry": "Biotechnology", "Address": "28 Wells Avenue, Yonkers, NY, United States, 10701", "FullTimeEmployees": "24", "FiscalYearEnd": "December", "LatestQuarter": "2020-06-30", "MarketCapitalization": "149892128", "EBITDA": "-30248390", "PERatio": "18.8", "PEGRatio": "0", "BookValue": "0.513", "DividendPerShare": "None", "DividendYield": "0", "EPS": "0.44", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "-0.4277", "ReturnOnEquityTTM": "-3.4874", "RevenueTTM": "0", "GrossProfitTTM": "-1698063", "DilutedEPSTTM": "-3.119", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "15.67", "TrailingPE": "18.8", "ForwardPE": "0", "PriceToSalesRatioTTM": "0", "PriceToBookRatio": "10.0338", "EVToRevenue": "0", "EVToEBITDA": "0", "Beta": "1.0104", "52WeekHigh": "12.1", "52WeekLow": "0.28", "50DayMovingAverage": "5.6856", "200DayMovingAverage": "6.51", "SharesOutstanding": "27804000", "SharesFloat": "19858366", "SharesShort": "1587321", "SharesShortPriorMonth": "897061", "ShortRatio": "5.1", "ShortPercentOutstanding": "0.05", "ShortPercentFloat": "0.0552", "PercentInsiders": "15.896", "PercentInstitutions": "37.752", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "1:10", "LastSplitDate": "2020-02-04"}